Ginkgo Bioworks buys Dutch microbe company ahead of going public

By Sean Whooley | May 17, 2021

Ginkgo Bioworks announced today that it agreed to acquire fungal platform technology developer Dutch DNA ahead of going public.

Last week, the Boston-based cell programming platform developer announced that it was combining with Soaring Eagle Acquisition Corp. to go public. The SPAC values Ginkgo at $15 billion and is expected to provide up to $2.5 billion in primary proceeds, while institutional investors committed $775 million in an oversubscribed private investment in public equity, according to a news release.

Get the full story from our sister site, Drug Delivery Business.

About The Author

Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.